EC grants orphan drug status to NS Pharma’s EGPA candidate
NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor, being developed to treat EGPA by restraining…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Jan 24
NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor, being developed to treat EGPA by restraining…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jan 24
The late-stage trial is evaluating the Trop-2-directed antibody-drug conjugate in 603 previously treated metastatic NSCLC in comparison to…
23 Jan 24
Inhalation Sciences AB has entered a new partnership with Actarmo Medical GmbH, a respiratory drug development services provider…
22 Jan 24
The approval was based on the positive findings from the pivotal, global ALPHA Phase 3 trial in which…
22 Jan 24
The fast track status follows the recent Investigational New Drug (IND) clearance for the candidate for use in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Jan 24
EVO756 is a highly selective, potent small molecule antagonist of mas-related G-protein coupled receptor X2, designed to block…
19 Jan 24
Founded in 2019, Summit Biosciences is an intranasal drug-delivery contract development and manufacturing organisation serving the unit dose…
19 Jan 24
Both firms will work to understand rare tumours in patients treated with immune checkpoint inhibitors by characterising their…
19 Jan 24
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
19 Jan 24
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally